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this rarity remains unexplained. This 
rarity contrasts with the observation 
that cases and outbreaks are more com-
mon in other parts of the developed 
world, particularly in northern climes 
(1,5,6–8). The recent appearance of epi-
zootic Y. pseudotuberculosis in farmed 
deer in the southern United States sug-
gests that this could change (9).
The high proportion of Y. pseudo-
tuberculosis cases that were diag-
nosed by blood culture suggests that 
less invasive Y. pseudotuberculosis 
infections are underrecognized in the 
United States. Diagnosis of Yersinia 
infections is difﬁ  cult without speciﬁ  c 
culture, Yersinia is not routinely tested 
for in the United States, and isolation 
of the organism by culture may be 
difﬁ  cult with standard media (2,10). 
Clinical diagnosis of Y. pseudotuber-
culosis infections can be challenging 
because physicians are not aware that 
Y. pseudotuberculosis is a potential 
cause of gastroenteritis (10). In the 
syndrome of pseudoappendicitis, the 
distinctive  ﬁ   ndings found by surgi-
cal exploration of severe mesenteric 
lymphadenitis can be suggestive, but 
diagnosis would require conﬁ  rmation 
by culture of nodes or feces (2,3).
Unless the physician is both aware 
of Y. pseudotuberculosis as a cause of 
gastroenteritis and knows which diag-
nostic test to order, Y. pseudotubercu-
losis infections will go undiagnosed. 
Clinicians should consider Y. pseudo-
tuberculosis as a cause of gastroenteri-
tis and pseudoappendicitis and request 
appropriate microbiologic testing 
for patients with suspected cases. If 
more cases are identiﬁ  ed in the Unit-
ed States, another investigation of Y. 
pseudotuberculosis might clarify the 
epidemiology of this infection.
Cherie Long, Timothy F. Jones, 
Duc J. Vugia, Joni Scheftel, 
Nancy Strockbine, 
Patricia Ryan, 
Beletshachew Shiferaw, 
Robert V. Tauxe, 
and L. Hannah Gould
Author afﬁ   liations: Georgia Department of 
Human Resources, Atlanta, Georgia, USA 
(C. Long); Atlanta Research and Educa-
tion Foundation, Atlanta (C. Long); Ten-
nessee Department of Health, Nashville, 
Tennessee, USA (T.F. Jones); California 
Department of Public Health, Richmond, 
California, USA (D.J. Vugia); Minnesota 
Department of Health, St. Paul, Minneso-
ta, USA (J. Scheftel); Centers for Disease 
Control and Prevention, Atlanta (N. Strock-
bine, R.V. Tauxe, L.H. Gould); Maryland 
Department of Health and Mental Hygiene, 
Baltimore, Maryland, USA (P. Ryan); and 
Oregon Department of Human Services, 
Portland, Oregon, USA (B. Shiferaw)
DOI: 10.3201/eid1603.091106
References
  1.   Hnatko SI, Rodin AE. Pasteurella pseudo-
tuberculosis infection in man. Can Med 
Assoc J. 1963;88:1108–12.
  2.   Paff JR, Triplett DA, Saari TN. Clinical 
and laboratory aspects of Yersinia pseudo-
tuberculosis infections, with a report of two 
cases. Am J Clin Pathol. 1976;66:101–10.
  3.   Hubbert  WT,  Petenyi  CW,  Glasgow 
LA, Uyeda CT, Creighton SA. Yersinia 
pseudotuberculosis infection in the United 
States. Septicema, appendicitis, and mes-
enteric lymphadenitis. Am J Trop Med 
Hyg. 1971;20:679–84.
  4.   Toma S. Human and nonhuman infections 
caused by Yersinia pseudotuberculosis in 
Canada from 1962 to 1985. J Clin Micro-
biol. 1986;24:465–6.
  5.   Nuorti JP, Niskanen T, Hallanvuo S, Mik-
kola J, Kela E, Hatakka M, et al. A wide-
spread outbreak of Yersinia pseudotuber-
culosis O:3 infection from iceberg lettuce. 
J Infect Dis. 2004;189:766–74. DOI: 
10.1086/381766
    6.   Jalava K, Hallanvuo S, Nakari UM, 
Ruutu P, Kela E, Heinasmaki T, et al. 
Multiple outbreaks of Yersinia pseudotu-
berculosis infections in Finland. J Clin Mi-
crobiol. 2004;42:2789–91. DOI: 10.1128/
JCM.42.6.2789-2791.2004
    7.    Vincent P, Leclercq A, Martin L, Duez 
JM, Simonet M, Carniel E. Sudden onset 
of pseudotuberculosis in humans, France, 
2004–05. Emerg Infect Dis. 2008;14:1119–
22. DOI: 10.3201/eid1407.071339
  8.   Tertti R, Granfors K, Lehtonen OP, Mert-
sola J, Makela AL, Valimaki I, et al. An 
outbreak of Yersinia pseudotuberculosis 
infection. J Infect Dis. 1984;149:245–50.
  9.   Zhang S, Zhang Z, Liu S, Bingham W, 
Wilson F. Fatal yersiniosis in farmed deer 
caused by Yersinia pseudotuberculosis 
serotype O:3 encoding a mannosyltrans-
ferase-like protein WbyK. J Vet Diagn 
Invest. 2008;20:356–9.
10.   Knapp W. Mesenteric adenitis due to 
Pasteurella pseudotuberculosis in young 
people. N Engl J Med. 1958;259:776–8.
Address for correspondence: L. Hannah Gould, 
Centers for Disease Control and Prevention, 
1600 Clifton Rd NE, Mailstop F22, Atlanta, GA 
30333, USA; email: lgould@cdc.gov
Measles Outbreak, 
the Netherlands, 
2008
To the Editor: From June 1 
through October 16, 2008, an outbreak 
of 99 reported measles cases occurred 
in the Netherlands (1). This outbreak 
was the largest measles outbreak in the 
Netherlands since 1999–2000, when 
>3,200 cases, including 3 deaths, were 
reported (2).
In the Netherlands, clinical symp-
toms compatible with measles in a per-
son with laboratory-conﬁ  rmed measles 
virus infection or an epidemiologic 
link to a laboratory-conﬁ  rmed  case 
are notiﬁ  able (i.e., must be reported 
to public health authorities). The Na-
tional Measles Reference Laboratory 
conducts genotyping and submits se-
quences to the World Health Organi-
zation European Region Measles Nu-
cleotide Surveillance database (www.
hpa-bioinformatics.org.uk/Measles/
Public/Web_Front/main.php). 
Of the 99 measles cases reported 
in the 2008 outbreak, 40 were labora-
tory conﬁ  rmed and 59 were notiﬁ  ed 
based on an epidemiologic link. The 
ﬁ  rst case-patient in the outbreak was 
a 6-year-old unvaccinated resident of 
The Hague who had not been abroad 
in the month before onset of illness. 
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The source of her infection was un-
known. She attended a school based 
on anthroposophic principles; the 
school had an estimated measles-
mumps-rubella (MMR) vaccination 
coverage of 80% (M. Monné-van Wir-
dum, pers. comm.). Subsequently, 52 
additional cases were reported from 
this and from another anthroposophic 
school in The Hague (cluster 1; on-
line Appendix Figure, www.cdc.gov/
EID/content/16/3/567-appF.htm). 
Two months after the ﬁ  rst case, 22 
additional cases were reported associ-
ated with an anthroposophic summer 
camp in the east of the Netherlands 
(cluster 2; online Appendix Figure). 
Five additional cases had an epide-
miologic link with an anthroposophic 
summer camp in France (cluster 3, 2 
cases; online Appendix Figure) and 
Switzerland (cluster 4, 3 cases; online 
Appendix Figure). No known measles 
patients in Switzerland were linked to 
this cluster (J. Richard, pers. comm.). 
Subsequently, 12 cases were reported 
that were associated with 2 daycare 
centers in the city of Utrecht (cluster 
5 and 6), both linked to an anthropo-
sophic community. From all 6 clusters 
and from 2 of the 7 cases with an un-
known source, indistinguishable mea-
sles viruses (genotype D8, 22 cases) 
were identiﬁ  ed. Given the low preva-
lence of this strain in Europe (J. Kre-
mer, pers. comm.), we concluded that 
virus transmission occurred between 
all 6 clusters. The ﬁ  rst cluster was not 
epidemiologically linked to any of the 
recent outbreaks in anthroposophic 
groups in Europe (3).
No case had an epidemiologic 
link to more than 1 cluster, suggesting 
the 6 cases introducing measles into 
these clusters were unreported. When 
the 7 cases with an unknown source 
were considered, this ﬁ  nding suggests 
that at least 13 cases were not reported 
(maximum reporting completeness 
88%). However, transmission through 
patients with subclinical cases may 
also have played a role (4).
There were no deaths. Four case-
patients (4%) were admitted to hos-
pitals. The median age was 9 years 
(range 8 months–48 years). Of the 
98 case-patients with information 
on vaccination status, 91 (93%) had 
been unvaccinated, 6 (6%) had had 1 
dose, none (0%) had had 2 doses, and 
1 (1%) had had 3 doses before onset 
of illness.  One of the 6 case-patients, 
vaccinated only once, had received 
her MMR vaccine only 11 days before 
the date of onset of illness and is hence 
not considered a vaccine failure. Of all 
99 case-patients, 91% had been eligi-
ble for >1 MMR vaccination accord-
ing to the vaccination schedule in the 
Netherlands. Of these cases, available 
information for 84 case-patients indi-
cated 48% (40 persons) were reported 
to be unvaccinated because of their 
anthroposophic beliefs, 49% (41 per-
sons) because of a critical attitude to-
wards vaccination, and 4% (3 persons) 
for other reasons.
Outbreak control plans in the 
Netherlands focus on protecting the 
population by adjusting the vaccina-
tion schedule during a nationwide 
outbreak (5). Studies are ongoing into 
knowledge and attitudes toward vac-
cination in communities with low vac-
cination coverage, aiming to identify 
opportunities to improve coverage.
The outbreak remained largely 
restricted to persons with philosophi-
cal objections to MMR vaccination, 
which suggests that there are sufﬁ  cient 
levels of herd immunity in the general 
population. Remarkably, no cases 
were reported from the Dutch Ortho-
dox Reformed Church community, de-
spite the low vaccine coverage in this 
group. This ﬁ  nding suggests that or-
thodox reformed and anthroposophic 
population subgroups have little direct 
contact, consistent with previous ob-
servations (6).
Measles vaccination was intro-
duced in the Netherlands in 1976. The 
single-dose regimen was in 1987 re-
placed by a 2-dose regimen of MMR 
vaccine; the ﬁ  rst dose at 14 months 
and the second at 9 years. The vac-
cination coverage for >1 MMR dose 
has been >95% from birth cohort 1986 
onward (7). During 2002–2007, the 
incidence of measles notiﬁ  cations in 
the Netherlands was below the World 
Health Organization regional thresh-
old for elimination (1/1 million pop-
ulation/year) (8). Nevertheless, this 
outbreak demonstrates the continued 
risk for measles transmission in the 
Netherlands. This suggests that indi-
cators based merely on incidence and 
national vaccination coverage are of 
limited usefulness for certiﬁ  cation of 
measles elimination. Data on measles 
seroprevalence and mixing patterns 
that will soon be available from the 
second national seroprevalence study 
will provide more insight into the dy-
namics of measles transmission in a 
population with pockets of low vacci-
nation coverage. These data will also 
help assess progress toward measles 
elimination from the Netherlands. 
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Neurologic 
Manifestations of 
Pandemic (H1N1) 
2009 Virus 
Infection 
To the Editor: In April 2009, 
the outbreak of inﬂ  uenza A pandemic 
(H1N1) 2009 virus was reported. Sub-
sequently, the disease spread through-
out the world, and the pandemic alert 
level was raised to level 6 in June by 
the World Health Organization. Pan-
demic (H1N1) 2009 virus infection 
spread to Thailand and is now found 
throughout Thailand. Similar to the 
effects of other viruses, pandemic 
(H1N1) 2009 virus may cause neuro-
logic complications. Associated neu-
rologic symptoms were ﬁ  rst reported 
from Dallas, Texas, USA: 4 children 
experienced unexplained seizures or 
had an alteration of consciousness 
level that was associated with this vi-
rus (1). We report an adult patient with 
pandemic (H1N1) 2009 infection who 
had neurologic complications.
A 34-year-old man, previously 
healthy, was admitted to Chaiyaphum 
Hospital in Chaiyaphum, Thailand, on 
August 24, 2009, with inﬂ  uenza-like 
symptoms. Two days after admission, 
progressive quadriparesis with bilater-
al, symmetric paresthesia (glove-and-
stocking pattern), and areﬂ  exia  de-
veloped. His motor weakness (grades 
III/V) began in both legs and then 
involved both arms and hands. Other 
neurologic examinations showed limi-
tation of extraocular movement in all 
directions, normal pupil size and light 
reﬂ  ex, and facial diplegia. A lumbar 
puncture was performed, and cerebro-
spinal  ﬂ   uid (CSF) contained neither 
leukocytes nor erythrocytes, with a 
protein level of 19.5 mg/dL.
On day 3 after the patient’s ad-
mission, acute respiratory failure de-
veloped. A nasopharyngeal aspirate 
specimen was positive for pandemic 
(H1N1) 2009 virus by PCR. The pa-
tient received oseltamivir, zanamivir, 
and ventilator support. His chest ra-
diograph showed diffuse alveolar in-
ﬁ  ltration. On day 10, his motor weak-
ness worsened to grade 0, and his 
consciousness level was diminished to 
a drowsy state.
A computed tomography scan of 
the brain showed diffuse white mat-
ter lesions (Figure). Repeated lumbar 
punctures continued to show CSF 
ﬁ   ndings within the reference range. 
An electrophysiologic study, electro-
myogram, and nerve conduction study 
showed polyneuropathy, axonopathy 
type. Guillain-Barré syndrome was 
suspected, and intravenous immuno-
globulin was given for 5 days. Tests 
for GQ1b and GM1 antibodies were 
carried out at Oxford University; re-
sults were negative.
Other laboratory tests showed 
mild transaminitis and negative results 
for syphilis testing and for serologic 
tests for HIV, hepatitis B virus, hepa-
titis C virus, Japanese encephalitis 
virus, herpes simplex virus, and My-
coplasma pneumoniae. A CSF antigen 
test was negative, and CSF culture 
was negative for bacteria. Meropenem 
was given to treat ventilator-associat-
ed pneumonia, which was caused by 
β-lactam–resistant  Klebsiella pneu-
moniae. After a month of treatment, 
the patient regained consciousness, 
his motor strength improved consider-
ably, and he was able to be gradually 
removed from the ventilator. After 3 
months, he was discharged with self-
assisted status. 
Our report shows neurologic 
manifestations associated with pan-
demic (H1N1) 2009 virus infection in 
an adult. The manifestation of progres-
sive quadriplegia with diffuse sensory 
loss is compatible with a polyneuropa-
thy. The neurologic signs developed 2 
days after the respiratory tract signs.
Although a diagnosis of Guil-
lain-Barré syndrome was considered 
initially, according to the National 
Institute of Neurologic Disorders and 
Stroke criteria (2), some clinical fea-
tures did not support this diagnosis. 
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